Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Cencora (COR) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Cencora is a member of our Medical group, which includes 949 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Cencora is currently sporting a Zacks Rank of #2 (Buy).Within the past quarter, the Zacks Consensus Estimate for COR's full-year earnings has moved 1.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.Based on the latest available data, COR has gained about 50.4% so far this year. Meanwhile, stocks in the Medical group have gained about 5% on average. This shows that Cencora is outperforming its peers so far this year.Another Medical stock, which has outperformed the sector so far this year, is CorMedix (CRMD). The stock has returned 39% year-to-date.For CorMedix, the consensus EPS estimate for the current year has increased 108.3% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).To break things down more, Cencora belongs to the Medical Services industry, a group that includes 62 individual companies and currently sits at #144 in the Zacks Industry Rank. This group has gained an average of 5.8% so far this year, so COR is performing better in this area. On the other hand, CorMedix belongs to the Medical - Biomedical and Genetics industry. This 467-stock industry is currently ranked #86. The industry has moved +18.9% year to date.Investors with an interest in Medical stocks should continue to track Cencora and CorMedix. These stocks will be looking to continue their solid performance.Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR): Free Stock Analysis Report CorMedix Inc (CRMD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks